Madrigal Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatotic liver disease (MASH).
Earnings
Next report
Jul 30, 2026 (Tomorrow)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
By net margin
Profile
Madrigal Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatotic liver disease (MASH). Its core value proposition centers on Rezdiffra, the first FDA-approved therapy for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The company is leveraging its first-to-market advantage to establish a leadership position in the MASH treatment landscape while expanding its pipeline through strategic acquisitions and internal development.
Madrigal holds a first-mover advantage as the first company to receive both FDA and EC approval for a MASH-specific treatment. It maintains a leading position through extensive clinical data and a growing pipeline of complementary mechanisms.
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s market cap?
- Madrigal Pharmaceuticals, Inc. (MDGL) has a market capitalization of $12.7B and trades on NASDAQ.
- What is Madrigal Pharmaceuticals, Inc.'s revenue and profitability?
- Madrigal Pharmaceuticals, Inc. generated $1.1B in trailing twelve-month revenue with a net loss of $309.4M, representing a net margin of -27.3%. Gross margin stands at 96.5%, with free cash flow of -$440.3M. These figures are based on the Q1 2026 filing.
- Who are Madrigal Pharmaceuticals, Inc.'s competitors?
- Madrigal Pharmaceuticals, Inc.'s key competitors include Eli Lilly and Company, Viking Therapeutics, Altimmune, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Madrigal Pharmaceuticals, Inc. partner with?
- Madrigal Pharmaceuticals, Inc.'s notable partners include Hoffmann-La Roche, CSPC Pharmaceutical Group Limited, Pfizer, and others.
- Where is Madrigal Pharmaceuticals, Inc. headquartered?
- Madrigal Pharmaceuticals, Inc. is headquartered in United States of America and employs approximately 376 people. It has been publicly traded since 2007.
